TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05626569
Drug: PD-1 combined with SBRT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-PD1 monoclonal antibody combined with SBRT. The SBRT defined as the radiation prescription with single dose equal or over 4Gy and the fractions less or equal to 10 fractions. BED equal or over 50Gy is required.
Study: NCT04960215
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A soft gelatin capsule containing soy oil, 5 capsules a day.
Study: NCT05012423
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo will be administered as oral capsules.
Study: NCT05012423
Drug: ECC0509
Approvals — FDA: no, EMA: no, PMDA: no
Description: ECC0509 1 mg and 10 mg capsules. ECC0509 will be administered as oral capsules.
Study: NCT05012423
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo will be given orally during each dosing day.
Study: NCT05012423
Drug: ECC0509
Approvals — FDA: no, EMA: no, PMDA: no
Description: ECC0509 1 mg and 10 mg capsules
Study: NCT05162118
Drug: Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell)) in combination with Nivolumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intratumoral injection of VG161 on day 1 only or day 1 through 3, in combination of Nivolumab intravenous injection only, Once every 2 weeks, 3 mg/kg each time.
Study: NCT05395143
Drug: Zinc sulfate
Normalized name: Zinc Sulfate
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zinc sulfate tablet 30mg once daily orally for 8 weeks along with Atorvastatin.
Study: NCT05395143
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet 30mg once daily orally for 8 weeks along with Atorvastatin.
Study: NCT05399888
Drug: BIIB080
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as specified in the treatment arm.
Study: NCT05399888
Drug: BIIB080-matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as specified in the treatment arm.
Study: NCT05469360
Drug: NIO752
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single intrathecal (cerebrospinal) injection of NIO752 of Dose A
Study: NCT05469360
Drug: NIO752
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single intrathecal (cerebrospinal) injection of NIO752 at dose B
Study: NCT05469360
Drug: Matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single intrathecal injection of matching placebo
Study: NCT03787290
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: participants will receive a single subcutaneous injection of saline
Study: NCT05251662
Drug: IBI305
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5mg/kg IV d1 Q3W
Study: NCT01240382
Drug: 3% DE-089 ophthalmic solution
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05419674
Drug: Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antibiotic for H. pylori eradication
Study: NCT01533532
Drug: KLH-2109
Normalized name: LINZAGOLIX CHOLINE 1 kg in 1 kg POWDER [KLH-2109 Choline]
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01533532
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT06443671
Drug: CapeOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Receiving CapeOX treatment for up to four cycles before surgery:~Capecitabine: 1000mg/m2, BID, PO, D1-14, Q3W; Oxaliplatin: 130 mg/m2, intravenous drip for 0-2 hours, D1, Q3W.
Study: NCT05322096
Drug: RGH-706
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules~Oral administration
Study: NCT05322096
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules~Oral administration
Study: NCT05093582
Drug: Levcromakalim
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 active episodic patients, 15 episodic patients in remission and 20 chronic patients of both genders are randomized to receive a 20-minute infusion of levcromakalim and/or sterile saline on two days, with at least 3 days in between.
Study: NCT04959448
Drug: DUPIXENT®
Approvals — FDA: no, EMA: no, PMDA: no
Description: No investigational agents will be provided. All treatments will be prescribed at the discretion of the study physician and other healthcare providers.
Study: NCT05034120
Drug: XZP-3621
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administer a single dose of XZP-3621 tablet after a low-fat meal.
Study: NCT05034120
Drug: XZP-3621
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cycle1(D1-D9): Administer the XZP-3621 tablet on an empty stomach in a single dose on Day1; Cycle2(D10-D18): Administer the XZP-3621 tablet after a high-fat meal in a single dose on Day10; Cycle3(D19-D27): Administer the XZP-3621 tablet after a standard meal in a single dose on Day19.
Study: NCT05034120
Drug: XZP-3621
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cycle1(D1-D9) : Administer the XZP-3621 tablet after a high-fat meal in a single dose on Day1; Cycle2(D10-D18): Administer the XZP-3621 tablet after a standard meal in a single dose on Day10; Cycle3(D19-D27): Administer the XZP-3621 tablet after on an empty stomach in a single dose on Day19.
Study: NCT05034120
Drug: XZP-3621
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cycle1(D1-D9): Administer the XZP-3621 tablet after a standard meal in a single dose on Day1; Cycle2(D10-D18): Administer the XZP-3621 tablet on an empty stomach in a single dose on Day10; Cycle3(D19-D27): Administer the XZP-3621 tablet after a high-fat meal in a single dose on Day19.
Study: NCT05034120
Drug: XZP-3621
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cycle1(D1-D9) : Administer the XZP-3621 tablet on an empty stomach in a single dose on Day1; Cycle2(D10-D18): Administer the XZP-3621 tablet after a standard meal in a single dose on Day10; Cycle3(D19-D27): Administer the XZP-3621 tablet after a high-fat meal in a single dose on Day19.
Study: NCT05034120
Drug: XZP-3621
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cycle1(D1-D9): Administer the XZP-3621 tablet after a high-fat meal in a single dose on Day1; Cycle2(D10-D18): Administer the XZP-3621 tablet on an empty stomach in a single dose on Day10; Cycle3(D19-D27): Administer the XZP-3621 tablet after a standard meal in a single dose on Day19.
Study: NCT05034120
Drug: XZP-3621
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cycle1(D1-D9): Administer the XZP-3621 tablet after a standard meal in a single dose on Day1; Cycle2(D10-D18): Administer the XZP-3621 tablet after a high-fat meal in a single dose on Day10; Cycle3(D19-D27): Administer the XZP-3621 tablet on an empty stomach in a single dose on Day19.
Study: NCT05350020
Drug: Hydrocortisone 100mg/ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: Licensed medicine used in clinical practice. Preparations will be used unmodified in this trial within marketing authorisations.
Study: NCT04831294
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally. Participants will place the liquid in their mouth for 45 seconds before swallowing it.
Study: NCT04936490
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg/d
Study: NCT06244368
Drug: GVM±R regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitoxantrone hydrochloride liposome (18 mg/m\^2) on day 1； Gemcitabine (800 mg/m\^2) on day 1,8； Vinorelbine (20mg/m\^2) on day 1,8； Rituximab (375mg/m\^2) on day 1;~The regimen will be administered every 3 weeks, for a maximum of 6 cycles. The choice of CD20 monoclonal antibody will be determined by the attending physician.
Study: NCT05478551
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline will serve as the placebo control on the contralateral side of the back.
Study: NCT04990440
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive placebo IV.
Study: NCT05830045
Drug: QLP2117
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT03548246
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily placebo for 2 years.
Study: NCT03548246
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone will be administered at a starting dose of 7-9 mg/M2/d and adjusted as necessary based on 17-hydroxyprogesterone and ACTH levels.
Study: NCT06471647
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo - dextrose
Study: NCT05630196
Drug: LY3857210
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT05630196
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT05204784
Drug: Intravenous Infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care treatment consists of intravenous iloprost infusions at a dose of 0.5-2 ng/kg/min administered over at least 6 hours as per local standard
Study: NCT05007808
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle Gel for topical administration
Study: NCT00533247
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04679883
Drug: 5% GLH8NDE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% GLH8NDE as eye drops
Study: NCT04679883
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo as eye drops
Study: NCT06479473
Drug: Chemoimmunotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: atients assigned to chemoimmunotherapy group would receive 4 to 6 cycles of chemoimmunotherapy followed by consolidative immunotherapy
Study: NCT05806307
Drug: Bupivacaine Hydrochloride 0.5 % Injectable Solution epinephrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 patient infiltration of the serosa and / or myometrium overlying the leiomyoma before uterine incision with a solution composed of 50 ml Bupivacaine Hcl 0.25% (Bucain® Weimer pharma, for Actavis Group PTC) and 0.5 mg of epinephrine Hcl (2 vials of Epinephrine® 0.25mg/1ml Misr Co. for Pharmaceutical Industries).
Study: NCT06387368
Drug: Huaier Granule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Huaier Granules: Oral administration, 10g once, 3 times a day. Capecitabine: oral administration, 1250mg/m\^2, twice a day (2500mg/m\^2/d), day 1-14, once every 3 weeks.
Study: NCT06387368
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral administration, 1250mg/m\^2, twice a day (2500mg/m\^2/d), day 1-14, once every 3 weeks.
Study: NCT05235230
Drug: Reference product (R) 25 mg Film Coated Tablets
Normalized name: ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Reference product (R) 25 mg Film Coated Tablets
Study: NCT05390892
Drug: GLP-1 receptor agonist
Normalized name: GLP-1 receptor agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dulaglutide, liraglutide, semaglutide
Study: NCT05653180
Drug: IBI310
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2mg/kg IV,3 weeks later, 1mg/kg IV Q6W
Study: NCT05134441
Drug: Placebo matching IMU-838 tablets
Normalized name: PLACEBO TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients are randomized to IMU-838 or placebo in ratio 1:1
Study: NCT06310837
Drug: Corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients received no less than 1 mg / kg.d glucocorticoid at week 0, then implemented according to the standard reduction scheme.
Study: NCT06310837
Drug: Immunosuppressive Agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mycophenolate mofetil 1g bid for more than 3 months, maintenance dose not less than 0.5g bid
Study: NCT05276297
Drug: GSK3228836
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 doses of GSK3228836 study intervention administered subcutaneously once per week for 12 weeks (Day 1 up to Day 78) to participants in ASO12-TI and ASO12 groups, or for 24 weeks (Day 1 up to Day 162) to participants in ASO24-TI and ASO24 groups, plus loading doses administered at Day 4 and Day 11 (2 doses each day) to participants in all groups during Treatment 1 period.
Study: NCT05182697
Drug: SCI-210
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral CBD oil plus pills of CannAmide (palmitoylethanolamide (PEA) 400 mg twice daily
Study: NCT06481787
Drug: Zuojin Pills
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zuojin Pills should be taken 30min after breakfast and dinner.
Study: NCT05182697
Drug: Oral CBD oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBD- active CBD oil with twice daily CannAmide Placebo pills matched in appearance and taste to CannAmide active pill.
Study: NCT05251584
Drug: Gentamicin
Normalized name: Gentamicin
DrugBank: Gentamicin (DB00798)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Apply gentamicin creams for prevention of peritoneal dialysis-related infection for 1 year start after 1 January 2022
Study: NCT06308393
Drug: RSS0393 ointment；Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: RSS0393 ointment；RSS0393 ointment placebo
Study: NCT05513924
Drug: 5Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The affected area cleaned with betadine surgical solution followed by alcohol 70%.~Local anesthetic, pridocaine cream, applied on the treated area under occlusion for 30 min before the procedure.~Using automated microneedling device (Dr Pen Derma Pen Ultima A6®) , which has a disposable head that personalized for each patient and sterilized after each session.~The derma pen will penetrate the skin with variable depths ranging from 0.25 to 0.5 mm (not more than the depth of the epidermis). It will pass vertically over the vitiligo area in a circular pattern until pinpoint bleeding appears.~Topical application of 5-fluorouracil 5% solution will be rubbed over the affected area for about 2 minutes. Occlusive dressing for hours.~This procedure will be repeated every two weeks for six months.
Study: NCT04072874
Drug: Experimental topical (Curaleish Topical)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curaleish is a formulation in lotion and cream. Curaleish lotion and Curaleish cream will be applied topically by each participant in all lesion until day 28 or 42, depending on the regimen to be evaluated. Study staff will be closely observing the safety assessment. The application until Day 28 or 42 will continue, even if the lesion has shown 100% re-epithelization before day 28 or day 42.
Study: NCT04755868
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The Arm B (Control arm) Maintenance therapy with placebo (once daily 1.0 mg oral administration), 103patients
Study: NCT05228041
Drug: Biologic treatments available in CRSwNP (dupilumab, mepolizumab and benralizumab according to their marketing approval)
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug prescription according to their marketing approval (subcutaneously, every month or every two weeks)
Study: NCT06064175
Drug: Ibuprofen 400 mg
Normalized name: ibuprofen 400 MG
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will receive ibuprofen 400 mg/4 ml via the parenteral route as a rapid 10-minute infusion in 150 ml of saline solution (0.09% NaCl).
Study: NCT06064175
Drug: Ibuprofen 800 mg
Normalized name: ibuprofen 800 MG
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will receive ibuprofen 800 mg/8 ml via the parenteral route as a rapid 10-minute infusion in 150 ml of saline solution (0.09% NaCl).
Study: NCT04341935
Drug: Insulin regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care insulin regimen as per hospital protocol
Study: NCT05197439
Drug: 0.9% saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: The 0.9% saline is administered with the same volume at the same speed as the other group.
Study: NCT04950504
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: CNP-201 Placebo
Study: NCT04325880
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in this arm will receive placebo oral tablet once daily
Study: NCT05076227
Drug: IM injection of vaccination (mRNA vaccination)
Normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
Approvals — FDA: no, EMA: no, PMDA: no
Description: mRNA vaccination
Study: NCT05076227
Drug: IM injection of vaccination (vector based vaccination)
Normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
Approvals — FDA: no, EMA: no, PMDA: no
Description: vector based vaccination
Study: NCT06355193
Drug: Langenlianqiao
Approvals — FDA: no, EMA: no, PMDA: no
Description: The data of patients with COVID-19 mild disease treated in our Hospital from November to December 2022 were collected, and the patients were divided into 100 cases of langenlianqiao(LGLQ) treatment group, 100 cases of LianhuaQingWen(LHQW) treatment group, and 53 cases of placebo control group according to the treatments they received, and the proportion of occurrence of major clinical symptoms, the time of symptom disappearance, and the number of days in hospitalization, and the duration of infection were compared among the three groups.
Study: NCT06425705
Drug: Silymarin
Normalized name: silymarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 140 mg of silymarin administered orally three times daily, alongside their standard treatment with renin-angiotensin system inhibitors.
Study: NCT06425705
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo capsule three times a day alongside their standard treatment with renin-angiotensin system inhibitors.
Study: NCT06355193
Drug: LianhuaQingWen
Approvals — FDA: no, EMA: no, PMDA: no
Description: The data of patients with COVID-19 mild disease treated in our Hospital from November to December 2022 were collected, and the patients were divided into 100 cases of langenlianqiao(LGLQ) treatment group, 100 cases of LianhuaQingWen(LHQW) treatment group, and 53 cases of placebo control group according to the treatments they received, and the proportion of occurrence of major clinical symptoms, the time of symptom disappearance, and the number of days in hospitalization, and the duration of infection were compared among the three groups.
Study: NCT05074485
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous injection of 1 milliliter normal saline
Study: NCT05730062
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo comparator
Study: NCT06328140
Drug: FDA Approved antidepressant treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily treatment with an FDA approved antidepressant
Study: NCT05167526
Drug: ASP8731 Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT05212948
Drug: S-268019-b
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for IM injection
Study: NCT05212948
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline solution for IM injection
Study: NCT05265910
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet (tablet)
Study: NCT06259175
Drug: Amlodipine 5 mg + indapamide 1.25 mg + perindopril 5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: a triple fixed combination of Amlodipine , indapamide and perindopril combinations, was in a 3-month in accordance to the instruction for medical use approved in the Russian Federation
Study: NCT06259175
Drug: Amlodipine 5 mg + indapamide 2.5 mg + perindopril 10 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: a triple fixed combination of Amlodipine , indapamide and perindopril combinations, was in a 3-month in accordance to the instruction for medical use approved in the Russian Federation
Study: NCT06259175
Drug: Amlodipine 10 mg + indapamide 2.5 mg + perindopril 10 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: a triple fixed combination of Amlodipine , indapamide and perindopril combinations, was in a 3-month in accordance to the instruction for medical use approved in the Russian Federation
Study: NCT05367232
Drug: ICP-033 tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally, once a day, 28 days per cycle
Study: NCT05429021
Drug: IMM-BCP-01
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single dose of IMM-BCP-01
Study: NCT05429021
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching single dose of IMM-BCP-01
Study: NCT04640571
Drug: pravastatin and chenodeoxycholic acid, after metformin and placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: single oral dose of pravastatin 80 mg and chenodeoxycholic acid 250 mg
Study: NCT04640571
Drug: valacyclovir, chenodeoxycholic acid, and enalaprilat, after polysorbate 80 and placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: single oral dose of valacyclovir 500 mg, chenodeoxycholic acid 250 mg, and enalaprilat 20 mg
Study: NCT06282549
Drug: Telmisartan/Amlodipine/Chlorthalidone(Truset)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan/Amlodipine/Chlorthalidone 40/5/12.5 mg or Telmisartan/Amlodipine/Chlorthalidone 80/5/12.5 mg or Telmisartan/Amlodipine/Chlorthalidone 80/5/25 mg
Study: NCT05761444
Drug: Atozet 10/40 mg or 10/80 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atozet 10/40 mg or 10/80 mg Dosage Formulation: Tablet Dosing Instructions: oral. Take 1 tablet daily
Study: NCT05761444
Drug: Lipitor 40 mg or 80 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipitor 40 mg or 80 mg Dosage Formulation: Tablet Dosing Instructions: oral. Take 1 tablet daily
Study: NCT06391034
Drug: hyperpolarized pyruvate +/-urea (13C/15N)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT04617821
Drug: mFOLFIRINOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous oxaliplatin for 2 hours, day 1;Intravenous infusion of calcium formyl tetrahydrofolate (LV) for 2 h, day 1;Irinotecan intravenous infusion is added 30 minutes later for 90 minutes, day 1;Intravenous infusion of 5-fluorouracil (5-FU) continued for 46 hours.Repeat every 2 weeks for a total of 4-6 cycles.
Study: NCT04667104
Drug: PegIFN-alpha2a
Approvals — FDA: no, EMA: no, PMDA: no
Description: PegIFN-alpha2a injection will be administered subcutaneously once weekly.
Study: NCT05468346
Drug: [14C]-HEC585
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single Dose = Solution containing 200 mg/100 µCi \[14C\]-HEC585
Study: NCT05916573
Drug: HSK16149
Approvals — FDA: no, EMA: no, PMDA: no
Description: single oral adminiatration, 20mg
Study: NCT04706767
Drug: Saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients received the same volume of normal saline 10 min before the induction of anesthesia, and then normal saline (0.9%) was continuously infused in an equal volume until close of the pneumoperitoneum.